A FGFR4 inhibitor and its preparation and application

By developing 3-substituted ethynylbenzolamide compounds as FGFR4 inhibitors, the problem of difficulty in effectively inhibiting the FGFR4 signaling pathway in the prior art has been solved, and effective treatment of FGFR4-related malignant tumors has been achieved, especially in liver cancer, showing significant results. inhibitory effect.

CN115947693BActive Publication Date: 2024-11-05CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211628730.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-18
Publication Date
2024-11-05
Estimated Expiration
2042-12-18

AI Technical Summary

Technical Problem

The existing treatment methods are difficult to effectively inhibit the FGFR4 signaling pathway, resulting in poor treatment of malignant tumors, especially in liver cancer, where there is insufficient treatment.

Method used

A 3-substituted ethynylbenzolamide compound was developed as an inhibitor of FGFR4, and the compound was prepared by a specific synthetic route for inhibiting FGFR4 kinase and in turn for the treatment of malignant tumors associated with FGFR4.

Benefits of technology

This compound showed highly selective inhibition of FGFR4 kinase, significantly inhibiting the proliferation and metastasis of tumor cells, and had potential effects in the treatment of FGFR4-related diseases such as liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115947693B_ABST
    Figure CN115947693B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a FGFR4 inhibitor and its preparation and application. The FGFR4 inhibitor is shown in general formula I, has good FGFR4 inhibitory activity and high FGFR4 selectivity, and can be used to treat malignant tumors closely related to this kinase.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a FGFR4 inhibitor and a preparation and application thereof. Background Art

[0002] FGFR (fibroblast growth factor receptor) is a receptor-type protein tyrosine kinase, including FGFR1, FGFR2, FGFR3, FGFR4 and other high-affinity receptors for 18 different FGF ligands, which play a key role in maintaining cell growth, proliferation, apoptosis, migration, etc. Each subtype has the structural characteristics of the extracellular region that binds to the ligand, the transmembrane region and the intracellular region of the receptor phosphorylation, and is part of the tyrosine kinase signaling pathway responsible for cell proliferation and differentiation. They form a ternary complex with 18 different fibroblast growth factors (FGF), thereby initiating a series of signal transduction pathways. FGFR molecular changes can lead to abnormal FGF / FGFR signals, promote cell proliferation, new angiogenesis, invasion, metastasis, anti-apoptosis, etc., and are related to a wide range of human malignancies.

[0003] Studies have found that the FGF19 / FGFR4 signaling pathway promotes the survival, proliferation, invasion and metastasis of hepatocellular carcinoma cells through multiple pathways, indicating that the mechanism of action of the FGF19 / FGFR4 signaling pathway in the progression of liver cancer can provide a basis for its targeted treatment. Therefore, there is an urgent need to develop FGFR4 selective inhibitors to treat cancer patients driven by abnormal FGFR4 signals. Novel selective FGFR4 small molecule kinase inhibitors have gradually become a promising treatment method, and their research and development has received increasing attention. Summary of the invention

[0004] One object of the present invention is to provide a FGFR4 inhibitor represented by the general formula I or a pharmaceutically acceptable salt thereof. The 3-substituted ethynylbenzamide compounds represented by the general formula I have good FGFR4 inhibitory activity and high FGFR4 selectivity, and can be used to treat malignant tumors closely related to this kinase.

[0005] Another object of the present invention is to provide a method for preparing the compound of formula I or a pharmaceutically acceptable salt thereof.

[0006] Another object of the present invention is to provide a composition comprising a compound of the general formula I of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, as well as a composition comprising a compound of the general formula I of the present invention or a pharmaceutically acceptable salt thereof and another one or more drugs.

[0007] Another object of the present invention is to provide a method for treating and / or preventing FGFR4-related diseases using the compound of general formula I of the present invention or a pharmaceutically acceptable salt thereof, and use of the compound of general formula I of the present invention or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and / or preventing FGFR4-related diseases.

[0008] To achieve the above purpose, the present invention provides the following technical solutions:

[0009] In a first aspect, the present invention provides a FGFR4 inhibitor represented by Formula I or a pharmaceutically acceptable salt thereof:

[0010]

[0011] in,

[0012] R1 is selected from hydrogen, halogen, alkyl;

[0013] R2 is selected from vinyl, alkyl, haloalkyl, cycloalkyl, and the vinyl may be substituted by alkyl or alkylaminoalkyl;

[0014] R3 is selected from hydrogen, alkyl, alkoxy;

[0015] R4 is selected from heterocycloalkyl or heterocycloaryl.

[0016] In some preferred embodiments, R1 is selected from hydrogen, C 1-6 Alkyl; preferably, R1 is selected from hydrogen, methyl.

[0017] In some preferred embodiments, R2 is selected from vinyl, propenyl, N,N-dimethylpropen-1-yl, methyl, ethyl, chloromethyl, cyclopropyl; preferably, R2 is vinyl.

[0018] In some preferred embodiments, R3 is selected from hydrogen, methyl, methoxy.

[0019] In some preferred embodiments, R4 is selected from N-methylpiperazinyl, morpholinyl, 1,2,4-triazolyl.

[0020] In some specific embodiments, the present invention provides a FGFR4 inhibitor represented by Formula I-1 or a pharmaceutically acceptable salt thereof:

[0021]

[0022]

[0023] in,

[0024] R1 is selected from hydrogen, methyl;

[0025] R3 is selected from hydrogen, methyl, methoxy.

[0026] In a second aspect, the present invention provides the following compounds:

[0027]

[0028]

[0029] In a third aspect, the present invention provides a method for preparing a compound of formula I, the method comprising:

[0030] (1) the compound of formula (1) reacts with the compound of formula (2) to produce the compound of formula (3);

[0031] (2) the compound of formula (4) reacts with the compound of formula (5) to generate the compound of formula (6);

[0032] (3) the compound of formula (3) reacts with the compound of formula (6) to form a compound of formula (7);

[0033] (4) hydrolyzing the compound of formula (7) to obtain the compound of formula (8);

[0034] (5) condensing the compound of formula (8) with the compound of formula (9) to obtain the compound of formula (10);

[0035] (6) reducing the compound of formula (10) to obtain the compound of formula (11);

[0036] (7) The compound of formula (11) is reacted with a substituted acid chloride to obtain a compound of formula (I). The reaction scheme is as follows:

[0037]

[0038] In a fourth aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective dose of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0039] In a fifth aspect, the present invention relates to the use of a compound of general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating or preventing FGFR4-related diseases, especially in the preparation of a drug for treating and preventing liver cancer.

[0040] Explanation of terms

[0041] The "alkyl" in the present invention refers to a straight-chain or branched saturated hydrocarbon group, preferably C 1-6 Alkyl, more preferably C 1-3 Alkyl, suitable C 1-3 The alkyl group is methyl, ethyl, propyl or isopropyl.

[0042] The "halogen" described in the present invention refers to fluorine, chlorine, bromine or iodine.

[0043] The "alkoxy" in the present invention refers to an alkyl-O-, preferably C 1-6 Alkoxy, more preferably C 1-3 Alkoxy, suitable C 1-3 Alkoxy is methoxy, ethoxy, propoxy or isopropoxy.

[0044] The term "haloalkyl" as used herein refers to an alkyl group substituted with at least one halogen, preferably a C 1-6 Alkyl, more preferably halogen-substituted C 1-3 alkyl.

[0045] The "pharmaceutical composition" of the present invention refers to a mixture comprising any of the compounds described herein and one or more pharmaceutically acceptable carriers and / or excipients. The purpose of the pharmaceutical composition is to facilitate the administration of the compound to an organism. The composition is generally used to treat and / or prevent diseases mediated by FGFR. DETAILED DESCRIPTION

[0046] A method for preparing the above-mentioned phenylacetylene compounds targeting FGFR4, the steps are as follows: Example 1: Preparation of 3-((2-((2-acrylamido-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

[0047] Synthesis of Methyl 3-Ethynyl-4-Methylbenzoate

[0048]

[0049] Under ice bath conditions, methyl 3-iodo-4-methylbenzoate (4g, 14.5mmol) was dissolved in N, N-dimethylformamide (15ml), bis(triphenylphosphine)palladium dichloride (0.2g, 0.28mmol) and cuprous iodide (0.275g, 1.44mmol) were added, triethylamine solution (4.39g, 43.46mmol) was added dropwise, the system was replaced with nitrogen 3 times, ethynyltrimethylsilane was slowly added dropwise under ice bath conditions, the ice bath was removed after stirring for 10 minutes, the reaction mixture was reacted at room temperature for 2h, and then tetrabutylammonium fluoride (10% tetrahydrofuran solution, 4.6g, 17.6mmol) was added thereto. The reaction was stirred at room temperature for 30min. TLC monitoring showed that the reaction was complete. The reaction mixture was cooled to room temperature, and 100 ml of ethyl acetate was slowly added to quench the reaction. The reaction solution was filtered through diatomaceous earth to obtain a mother liquor. Water was added to the filtrate for extraction (100 ml × 3). The organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and concentrated to obtain a solid. The residue was purified by silica gel column chromatography to obtain 2.3 g of a white solid compound with a yield of 91%.

[0050] Synthesis of 5-iodo-N-(2-methyl-6-nitrophenyl)pyrimidin-2-amine

[0051]

[0052] Under ice bath conditions, weigh 2-amino-5-iodopyrimidine (3 g, 13.57 mmol) into a flask, add DMF and stir to make it evenly dispersed, react for 20 minutes, then slowly add 2-fluoro-3-nitrotoluene (2.74 g, 17.67 mmol) dropwise into the reaction flask, stir for 5 minutes, and react at 60°C for 2 hours. After the reaction is completed, cool to room temperature, add the reaction system to water, extract twice with ethyl acetate, combine the organic layers and wash with saturated brine, then dry over anhydrous sodium sulfate, remove the solvent under reduced pressure, concentrate and purify by silica gel column chromatography to obtain 3.8 g of light yellow solid compound with a yield of 78%.

[0053] Synthesis of methyl 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)benzoate

[0054]

[0055] The compounds methyl 3-ethynyl-4-methylbenzoate (2 g, 11.5 mmol), 5-iodo-N-(2-methyl-6-nitrophenyl)pyrimidin-2-amine (2.72 g, 7.66 mmol), bis(triphenylphosphine)palladium dichloride (0.12 g, 1.17 mmol) and cuprous iodide (0.33 g, 1.7 mmol) were weighed in sequence, put into a 250 mL reaction bottle, 15 mL of dry DMF solution was added to dissolve it, triethylamine solution (2.67 g, 26.4 mmol) was dropped into it, the system was replaced with nitrogen three times, and then reacted at room temperature for 2 h under nitrogen protection. The reaction was monitored by TLC until the raw material reaction was complete. 150 ml of ethyl acetate was added to quench the reaction. The reaction solution was filtered through diatomaceous earth to obtain the mother liquor. Water was added to the filtrate for extraction (150 ml×3). The organic layers were combined, washed with saturated brine, and then dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and concentrated to obtain a solid. The residue was purified by silica gel column chromatography to obtain 2.6 g of a yellow solid compound with a yield of 56%.

[0056] Synthesis of 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)benzoic acid

[0057]

[0058] In a 250 mL reaction bottle, methyl 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)benzoate (2.6 g, 6.5 mmol), potassium hydroxide (2.21 g, 39.5 mmol), 15 ml of ethanol and 3 mL of water were added in sequence, and the reaction was carried out at 60 ° C for 1 h. The reaction was monitored by TLC until the reaction was complete. The solvent was removed under reduced pressure, and 4 mol / L hydrochloric acid was slowly added to the residue under ice bath conditions to adjust the pH. After stirring for 5 min, a brown solid was precipitated, which was filtered and dried to obtain the target compound. It was purified by silica gel column chromatography to obtain 2 g of a yellow solid compound with a yield of 79.7%.

[0059] Synthesis of 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

[0060]

[0061] To a 250 mL reaction bottle, compound 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)benzoic acid (1.9 g, 4.89 mmol), HATU (2.23 g, 5.87 mmol) and 15 mL of dry DMF were added in sequence, DIEA (1.26 g, 9.76 mmol) was slowly added dropwise, and stirred at room temperature for 1 h. 4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline was added, and the reaction temperature was raised to 60 ° C for 5 h. TLC was monitored until the reaction of the raw material was complete, 150 mL of water was added to quench the reaction, and ethyl acetate (150 mL×3) was used for extraction. The organic phases were combined, washed with saturated NaCl in sequence, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.5 g of a light yellow solid compound with a yield of 79.4%.

[0062] Synthesis of 3-((2-((2-amino-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

[0063]

[0064] To a 250 mL reaction bottle was added the compound 4-methyl-3-(2-(2-methyl-6-nitrophenyl)amino)pyrimidin-5-yl)ethynyl)-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (2.5 g, 3.88 mmol), iron powder (1.09 g, 19.46 mmol), ammonium chloride (1.05 g, 19.44 mmol), 15 mL of ethanol and 3 mL of water. The mixture was heated under reflux at 90 °C for 1 h and monitored by TLC until the reaction was complete. The reaction solution was filtered through diatomaceous earth while hot to obtain a mother liquor. The solvent was removed under reduced pressure, and the mixture was extracted with saturated sodium carbonate, water and ethyl acetate (100 mL×3). The organic phases were combined and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography to obtain 600 mg of the compound as a light yellow solid in a yield of 25.2%.

[0065] Synthesis of 3-((2-((2-acrylamido-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

[0066]

[0067] Compound 3-((2-((2-amino-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (300 mg, 0.48 mmol) was placed in a 25 mL reaction bottle, 10 mL of dry DCM and triethylamine (98 mg, 0.97 mmol) were added, and the mixture was protected by nitrogen. Stirring was carried out under ice-salt bath for 10 min, and a solution of acryloyl chloride (88 mg, 0.97 mmol) in dichloromethane (1 mL) was slowly added dropwise. The raw material was monitored by TLC until the reaction was complete. 2 mL of ice water was added to quench the reaction, and the product was extracted with ethyl acetate (20 mL×3), washed with saturated sodium carbonate and saturated NaCl in turn, the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to obtain 80 mg of white powder with a yield of 14.7%. 1 H NMR(600MHz,DMSO-d6)δ10.51(s,1H),9.49(s,1H),8.82(s,1H),8.57(s,2H),8.20( d,J=2.2Hz,1H),8.12(d,J=2.0Hz,1H),8.06(m,1H),7.90(m,1H),7.70(d,J=8.6Hz,2 H),7.50(d,J=8.1Hz,1H),7.20(m,1H),7.12-7.07(m,1H),6.53(m,1H),6.23(m,1H), 5.71(m,1H),3.56(s,2H),2.52(s,3H),2.47-2.24(m,8H),2.16(s,3H),2.14(s,3H). 13 CNMR(151MHz,DMSO-d6)165.15,163.91,160.22,143.87,138.64,137.13,135.39,132.61,132.53,132.28,131.67,130.74,130.37, 128.47,127.72,127.30,126.97,126.76,123.95,122.75,117.73,107.86,90.94,89.65,57.92,55.15,53.13,46.14,20.87,18.84.

[0068] Example 2: Preparation of 3-(2-(2-(2-chloroacetamide)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0069]

[0070] The operation was the same as in Example 1, and 83 mg of a white solid was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.49(s,1H),9.39(s,1H),8.97(s,1H),8.58(m,2H), 8.20(d,J=2.2Hz,1H),8.13(d,J=2.0Hz,1H),8.06(m,1H),7.90(m,1H),7.71( m,2H),7.49(d,J=8.1Hz,1H),7.21(t,J=7.9Hz,1H),7.15-7.09(m,1H),4.29( s,2H),3.57(s,2H),2.53(s,3H),2.38-2.36(m,8H),2.20(s,3H),2.16(s,3H). 13 C NMR(151MHz,DMSO-d6)165.19,160.74,160.29,143.87,138.67,137.01,1 35.06,132.64,132.47,131.72,130.79,130.37,128.46,128.02,127.82, 127.12,126.92,123.98,123.58,123.18,122.76,121.07,117.82,116.09 ,108.04,91.01,89.57,57.88,55.05,52.90,45.89,43.75,20.84,18.68.

[0071] Example 3: Preparation of (E)-3-(2-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0072]

[0073] The operation was the same as in Example 1, and 60 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.60(s,1H),9.60(s,1H),8.91(s,1H),8.57(s,2H),8.24(d, J=2.2Hz,1H),8.14(d,J=2.0Hz,1H),8.09(m,1H),7.93(m,1H),7.71(t,J=8.7Hz,2H),7 .49(d,J=8.1Hz,1H),7.19(t,J=7.8Hz,1H),7.11-7.06(m,1H),6.73(m,1H),6.42(m,1H ),3.59(s,2H),3.15-3.10(m,2H),2.53(s,3H),2.28(s,3H),2.22(s,6H),2.14(s,3H). 13 C NMR(151MHz,DMSO-d6)δ165.18,163.86,160.64,160.18,143.84,140.83,138.74,1 37.12,135.47,132.57,132.27,131.69,130.80,130.35,129.71,128.48,127.98,12 7.78,127.04,126.82,126.72,125.70,123.99,123.89,122.76,121.48,117.79,117.75,107.85,90.93,89.64,59.81,57.74,54.72,52.41,45.38,45.21,20.86,18.85.

[0074] Example 4: Preparation of 4-methyl-3-((2-((2-methyl-6-propionamidophenyl)amino)pyrimidin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0075]

[0076] The operation was the same as in Example 1, and 78 mg of white powder was obtained by column chromatography. 1H NMR (600MHz, DMSO-d6) δ10.51(s,1H),9.21(s,1H),8.75(s,1H),8.57(s,2H),8.20(d,J=2.2 Hz,1H),8.12(d,J=2.0Hz,1H),8.05(m,1H),7.90(m,1H),7.70(d,J=8.5Hz,1H),7.58(d,J=8. 1Hz,1H),7.50(d,J=8.1Hz,1H),7.16(t,J=7.8Hz,1H),7.06(d,J=7.6Hz,1H),3.56(s,2H),2 .53(s,3H),2.50-2.32(m,8H),2.29(m,2H),2.16(s,3H),2.14(s,3H),1.01(t,J=7.5Hz,3H). 13 CNMR(151MHz,DMSO-d6)δ174.21,172.70,165.14,160.65,160.16,143.83,1 38.65,137.01,135.54,132.61,132.48,131.66,130.74,130.35,128.45,12 7.96,127.76,126.67,126.61,125.71,123.93,122.75,121.57,117.73,107.82,90.93,89.64,57.90,55.13,53.05,46.05,20.86,18.84,17.69,10.25.

[0077] Example 5: Preparation of 3-((2-((2-acrylamidophenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0078]

[0079] The operation was the same as in Example 1, and 50 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.51(s,1H),9.84(s,1H),9.10(s,1H),8.65(s,2H),8.2 1(d,J=2.2Hz,1H),8.14(d,J=2.0Hz,1H),8.06(m,1H),7.91(m,1H),7.74-7.68(m, 2H),7.64-7.57(m,1H),7.51(d,J=8.1Hz,1H),7.20(m,2H),6.52(m,1H),6.29(m, 1H),5.81-5.74(m,1H),3.57(s,2H),2.54(s,3H),2.45-2.22(m,8H),2.16(s,3H). 13 C NMR(151MHz,DMSO-d6)δ165.13,164.24,160.59,159.31,143.87,138.66, 132.65,132.53,131.99,131.68,131.15,130.83,130.36,128.52,128.00, 127.80,127.59,125.73,125.59,125.55,124.97,123.95,123.91,122.67, 117.79,117.74,108.83,91.28,89.42,57.94,55.18,53.12,46.11,20.86.

[0080] Example 6: Preparation of 3-((2-((2-acrylamide-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methoxy-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0081]

[0082] The operation was the same as in Example 1, and 120 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.42(s,1H),9.51(s,1H),8.80(s,1H),8.52(s,2H) ,8.17(m,2H),8.04(m,2H),7.70(t,J=7.5Hz,2H),7.25(d,J=8.8Hz,1H),7.1 9(t,J=7.8Hz,1H),7.10(d,J=7.6Hz,1H),6.54(m,1H),6.23(m,1H),5.77-5. 69(m,1H),3.94(s,3H),3.56(s,2H),2.36(s,8H),2.16(s,3H),2.14(s,3H). 13 C NMR(151MHz,DMSO-d6)δ164.76,163.93,162.43,160.55,160.10,138.76,13 7.12,135.36,132.73,132.33,131.65,130.93,129.84,127.93,127.74,127 .54,127.31,126.98,126.88,126.74,125.73,123.88,121.52,117.67,111.74,111.58,108.09,89.08,88.80,57.92,56.69,55.17,53.12,46.13,18.84.

[0083] Example 7: Preparation of 3-((2-((2-acrylamide-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0084]

[0085] The operation was the same as in Example 1, and 130 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.57(s,1H),9.48(s,1H),8.75-8.82(m,1H),8.55(s,2H), 8.21(d,J=2.3Hz,1H),8.13(d,J=1.8Hz,1H),8.05(m,1H),7.98(m,1H),7.76-7.67( m,3H),7.60(t,J=7.8Hz,1H),7.19(t,J=7.8Hz,1H),7.10(d,J=7.5Hz,1H),6.53(m, 1H),6.22(m,1H),5.71(m,1H),3.57(s,2H),2.37(m,8H),2.17(s,3H),2.14(s,3H). 13 C NMR(151MHz,DMSO-d6)δ165.29,163.93,160.76,160.15,138.64,137.12, 135.36,135.33,134.63,132.41,132.30,131.74,130.51,129.80,129.58, 128.51,128.00,127.81,127.30,126.98,126.75,123.98,123.86,122.96, 121.55,117.78,107.62,92.10,85.93,57.73,54.75,52.43,45.40,18.85.

[0086] Example 8: Preparation of 5-((2-((2-acrylamide-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-2-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0087]

[0088] The operation was the same as in Example 1, and 100 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.61(s,1H),9.47(s,1H),8.70-8.79(m,1H),8.51(s,2H) ,8.18(d,J=2.3Hz,1H),7.95(m,1H),7.74-7.61(m,3H),7.54(m,1H),7.37(d,J=8.1 Hz,1H),7.19(t,J=7.8Hz,1H),7.12-7.04(m,1H),6.52(m,1H),6.22(m,1H),5.76-5 .64(m,1H),3.57(s,2H),2.41(s,3H),2.40-2.31(m,8H),2.21(s,3H),2.13(s,3H). 13 CNMR(151MHz,DMSO-d6)δ167.47,163.92,160.65,160.09,138.67,137.29,1 37.12,136.95,135.34,132.72,132.43,132.29,131.82,131.73,130.40,128 .07,127.31,126.96,126.74,125.66,123.84,123.45,121.52,120.15,117.15,113.37,107.84,92.15,85.32,57.80,54.95,52.74,45.75,19.84,18.84.

[0089] Example 9: Preparation of 4-((2-((2-acrylamide-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-3-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0090]

[0091] The operation was the same as in Example 1, and 77 mg of white powder was obtained by column chromatography. 1H NMR(600MHz,DMSO-d6)δ10.78(d,J=4.2Hz,1H),9.91(s,1H),9.02(s,1H),8.56(s,2H),8 .29(d,J=2.2Hz,1H),8.14(m,1H),8.03(d,J=1.8Hz,1H),7.90(m,1H),7.69(t,J=9.7Hz, 2H),7.61(d,J=8.0Hz,1H),7.19(t,J=7.8Hz,1H),7.10(d,J=7.6Hz,1H),6.59(m,1H),6. 24(m,1H),5.71(m,1H),3.61(s,2H),2.70(s,3H),2.53(s,8H),2.43(s,3H),2.13(s,3H).

[0092] Example 10: Preparation of (E)-3-((6-((2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyridin-3-yl)ethynyl)-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0093]

[0094] The same operation as in Example 1 was performed and 101 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.60(s,1H),9.50(s,1H),8.52-8.40(m,1H),8.22(d,J=2.3Hz,2H), 8.12(s,1H),8.06(m,1H),7.97(m,1H),7.74(d,J=8.2Hz,1H),7.71(m,2H),7.63(m,1H),7.57 (t,J=7.8Hz,1H),7.17(t,J=7.8Hz,1H),7.08(d,J=7.5Hz,1H),6.68(m,1H),6.47(s,1H),6.3 7-6.31(m,1H),3.57(s,2H),3.00(m,2H),2.37(m,8H),2.16(s,3H),2.14(s,6H),2.13(s,3H). 13C NMR(151MHz,DMSO-d6)δ165.24,163.91,157.30,151.37,143.68,141.41,140.12,13 8.69,136.92,135.70,132.56,132.41,131.69,130.59,130.44,130.30,128.11,127 .97,127.78,126.95,126.66,126.50,125.71,123.96,123.90,123.20,121.59,117.77,117.72,108.27,92.96,88.24,60.02,57.85,55.01,52.87,49.06,45.43,18.83.

[0095] Example 11: Preparation of (E)-3-((2-(2-(but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0096]

[0097] The same operation as in Example 1 was performed and 88 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.54(s,1H),9.37(s,1H),8.81(s,1H),8.57(s,2H),8.22( d,J=2.2Hz,1H),8.13(d,J=2.0Hz,1H),8.08(m,1H),7.91(m,1H),7.69(m,2H),7.50( d,J=8.1Hz,1H),7.18(t,J=7.8Hz,1H),7.10-7.05(m,1H),6.78(m,1H),6.24(m,1H), 3.58(s,2H),2.51-2.53(s,3H),2.45(s,8H),2.29(s,3H),2.13(s,3H),1.84(m,3H). 13C NMR(151MHz,DMSO-d6)δ172.45,165.16,164.24,160.67,160.17,143.86,140 .47,138.72,137.12,135.55,132.59,132.28,131.72,130.75,130.37,129.69 ,128.46,127.99,127.79,126.75,126.35,125.70,123.96,122.75,121.37,117.77,107.86,90.94,89.66,57.74,54.76,52.45,45.41,20.87,18.85,17.92.

[0098] Example 12: Preparation of 3-((2-((2-acrylamide-4-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0099]

[0100] The same operation as in Example 1 was performed and 65 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.49(s,1H),9.76(s,1H),8.98(s,1H),8.61(s,2H),8.20(s ,1H),8.14(d,J=2.0Hz,1H),8.06(m,1H),7.91(m,1H),7.70(d,J=8.5Hz,1H),7.56(d ,J=8.2Hz,1H),7.50(d,J=8.1Hz,1H),7.43(s,1H),7.03(m,1H),6.51(m,1H),6.27(m ,1H),5.76(m,1H),3.57(s,2H),2.54(s,3H),2.40(s,8H),2.31(s,3H),2.18(s,3H). 13C NMR(151MHz,DMSO-d6)δ165.14,164.16,160.57,159.45,143.85,138.67,13 4.37,132.63,132.48,132.03,131.69,131.14,130.81,130.35,129.32,128 .49,128.00,127.80,127.49,126.24,125.65,125.17,123.95,122.71,117.79,117.75,108.54,91.19,89.50,57.91,55.10,53.00,45.98,21.05,20.85.

[0101] Example 13: Preparation of 3-((6-((2-acrylamide-6-methylphenyl)amino)pyridin-3-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0102]

[0103] The same operation as in Example 1 was performed and 110 mg of white powder was obtained by column chromatography. 1 H NMR (600MHz, DMSO-d6) δ10.49(s,1H),9.53(s,1H),8.35(s,1H),8.27-8.19(m,2H),8.10(d,J=2 .0Hz,1H),8.06(m,1H),7.90-7.86(m,1H),7.73(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.65(m ,1H),7.47(d,J=8.0Hz,1H),7.19(t,J=7.8Hz,1H),7.10(d,J=7.6Hz,1H),6.55-6.41(m,2H),6. 20(m,1H),5.69(m,1H),3.56(s,2H),2.51(s,3H),2.43-2.23(m,8H),2.16(s,3H),2.14(s,3H). 13C NMR (151MHz, DMSO-d6) δ165.22,163.88,157.26,151.34,143.64,140.08,138. 69,136.97,135.47,132.58,132.49,132.43,131.65,130.61,130.26,128.12, 127.97,127.77,127.04,126.43,125.73,123.98,123.92,123.20,121.68,117.81,117.77,108.34,92.95,88.28,57.95,55.20,53.17,46.16,20.85,18.86.

[0104] Example 14: Preparation of (E)-3-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide;

[0105]

[0106] The same operation as in Example 1 was performed and 100 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.30-10.24(m,1H),9.56(s,1H),8.88(s,1H),8.55(s,2H),8.10( d,J=2.0Hz,1H),7.94-7.87(m,1H),7.77-7.64(m,3H),7.46(d,J=8.0Hz,1H),7.25(d,J=8. 2Hz,2H),7.18(t,J=7.8Hz,1H),7.07(d,J=7.5Hz,1H),6.71(m,1H),6.38(m,1H),3.41(s,2 H),3.02(d,J=6.1Hz,2H),2.51(s,3H),2.33(m,8H),2.15(s,6H),2.14(s,3H),2.13(s,3H). 13C NMR(151MHz,DMSO-d6)δ164.81,164.01,160.61,160.18,143.40,141.85,138.36,137.11,135.50,134.05,133.16,130.82,130.22,129.79,12 9.46,128.40,126.79,126.67,126.41,122.69,121.51,120.72,107.94 ,91.05,89.53,62.16,60.19,55.23,52.98,46.20,45.60,20.82,18.84.

[0107] Example 15: Preparation of (E)-3-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(morpholinomethyl)phenyl)benzamide;

[0108]

[0109] The same operation as in Example 1 was performed and 90 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.31(t,J=3.6Hz,1H),9.70-9.57(m,1H),8.96-8.86(m,1H),8.55(s ,2H),8.11(d,J=1.9Hz,1H),7.92(m,1H),7.72(m,3H),7.46(d,J=8.1Hz,1H),7.27(d,J=8.4Hz ,2H),7.17(t,J=7.8Hz,1H),7.07(d,J=7.1Hz,1H),6.71(m,1H),6.39(m,1H),3.57(t,J=4.6Hz ,4H),3.43(s,2H),3.02(m,2H),2.51(s,3H),2.35(t,J=4.7Hz,4H),2.15(s,6H),2.13(s,3H). 13C NMR(151MHz,DMSO-d6)δ164.83,164.00,160.61,160.15,143.41,141.84,138.47,137.10,135.47,133.50,133.13,130.84,130.22,129.81 ,129.58,128.42,126.79,126.65,126.41,122.69,121.55,120.74,10 7.93,91.05,89.53,66.69,62.54,60.19,53.61,45.60,20.81,18.85.

[0110] Example 16: Preparation of (E)-3-(2-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazin-1-yl)phenyl)benzamide;

[0111]

[0112] The same operation as in Example 1 was performed and 70 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.14(s,1H),9.71(s,1H),8.95(s,1H),8.55(s,2H),8.13-8.07(m,1H),7 .94-7.88(m,1H),7.68(d,J=8.1Hz,1H),7.64(d,J=8.7Hz,2H),7.45(d,J=8.0Hz,1H),7.17(t,J=7. 8Hz,1H),7.07(d,J=7.6Hz,1H),6.91(d,J=8.7Hz,2H),6.71(m,1H),6.39(m,1H),3.32(s,3H),3.10 (t,J=4.9Hz,4H),3.02(d,J=6.0Hz,2H),2.46(s,4H),2.22(s,3H),2.14-2.17(s,6H),2.13(s,3H). 13C NMR(151MHz,DMSO-d6)δ164.30,164.00,160.60,160.12,148.01,143.11,141.80,137.10,135.43,133.30,131.43,130.75,130.16,129.92 ,129.85,128.31,126.80,126.61,126.44,122.63,122.04,115.88,10 7.95,91.11,89.43,60.19,55.12,48.98,46.24,45.60,20.79,18.86.

[0113] Example 17: Preparation of (E)-N-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-3-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methylbenzamide;

[0114]

[0115] The same operation as in Example 1 was performed and 86 mg of white powder was obtained by column chromatography. 1 H NMR (600MHz, DMSO-d6) δ10.36(d,J=7.1Hz,1H),9.58(t,J=9.2Hz,1H),8.89(d,J=9.3Hz,1H),8.65(s ,1H),8.55(s,2H),8.11(d,J=2.0Hz,1H),7.97(s,1H),7.91(m,1H),7.79(m,2H),7.70(d,J=8.1Hz,1 H),7.47(d,J=8.0Hz,1H),7.29(d,J=8.4Hz,2H),7.18(t,J=7.8Hz,1H),7.08(d,J=7.5Hz,1H),6.71( m,1H),6.38(m,1H),5.39(s,2H),3.02(d,J=4.3Hz,2H),2.51(s,3H),2.14-2.16(s,6H),2.14(s,3H). 13C NMR(151MHz,DMSO-d6)δ164.94,164.02,160.62,160.18,152.11,144.53,143.53,141.86,139.33,137.11,135.50,132.97,131.86,130.83, 130.25,129.79,128.76,128.44,126.79,126.67,126.40,122.71,121 .52,121.02,107.92,91.01,89.56,60.18,52.28,45.60,20.82,18.84.

[0116] Example 18: Preparation of 3-(2-((2-(2-(cyclopropanecarboxamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0117]

[0118] The same operation as in Example 1 was performed and 102 mg of white powder was obtained by column chromatography. 1 H NMR (600MHz, DMSO-d6) δ10.58-10.50(m,1H),9.73-9.54(m,1H),8.80(d,J=6.2Hz,1H),8.57(s, 2H),8.22(s,1H),8.14(s,1H),8.07(d,J=8.7Hz,1H),7.92(m,1H),7.69(d,J=8.5Hz,1H),7.59(d ,J=8.2Hz,1H),7.49(d,J=8.0Hz,1H),7.15(t,J=7.8Hz,1H),7.06(d,J=7.6Hz,1H),3.56(s,2H), 2.53(s,3H),2.36(m,8H),2.15-2.19(m,6H),1.89(s,1H),0.83-0.77(m,2H),0.70-0.77(m,2H). 13C NMR(151MHz,DMSO-d6)δ172.49,165.17,160.66,160.22,143.82,138.69,137.1 0,135.61,132.64,132.53,131.66,130.81,130.33,129.67,128.47,127.98,12 7.79,126.67,126.57,125.74,123.99,123.92,122.79,121.45,117.82,117.78,107.90,90.96,89.66,57.96,55.21,53.17,46.16,20.85,18.84,14.75,7.70.

[0119] Example 19: Preparation of (E)-3-(2-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(3-methyl-4-(4-methylpiperazine-1-carbonyl)phenyl)benzamide;

[0120]

[0121] The same operation as in Example 1 was performed and 60 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.30(d,J=6.5Hz,1H),9.43(s,1H),8.82(s,1H),8.56(s,2H),8.10(s ,1H),7.89(d,J=8.0Hz,1H),7.69(m,3H),7.48(d,J=8.2Hz,1H),7.18(t,J=7.9Hz,1H),7.13(d, J=8.2Hz,1H),7.08(d,J=7.6Hz,1H),6.71(m,1H),6.37(m,1H),3.65(s,2H),3.16(s,2H),3.02( d,J=6.0Hz,2H),2.52(s,3H),2.36(s,2H),2.22(s,5H),2.19(s,3H),2.15(s,6H),2.14(s,3H). 13C NMR(151MHz,DMSO-d6)δ168.87,165.01,163.92,160.62,160.18,143.59,1 41.38,139.73,137.10,135.49,134.76,132.94,132.10,130.79,130.27,12 9.66,128.42,126.78,126.71,126.68,122.70,122.10,121.43,118.07,107.86,90.97,89.57,59.98,55.28,54.78,46.02,45.40,20.83,19.40,18.83.

[0122] Example 20: Preparation of (E)-3-(2-((2-(2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-(4-methylpiperazine-1-carbonyl)-3-(trifluoromethyl)phenyl)benzamide;

[0123]

[0124] The same operation as in Example 1 was performed and 88 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.82(t,J=3.0Hz,1H),9.71-9.61(m,1H),8.93(s,1H),8.56(s,2H),8.35(d,J=2.1Hz,1H ),8.20(m,1H),8.17(d,J=2.0Hz,1H),7.98(m,1H),7.69(d,J=8.1Hz,1H),7.50(d,J=8.0Hz,1H),7.43(d,J=8.4Hz ,1H),7.18(t,J=7.8Hz,1H),7.08(d,J=7.5Hz,1H),6.71(m,1H),6.39(m,1H),3.63(m,2H),3.19-3.12(m,1H),3.1 0-3.04(m,1H),3.02(m,2H),2.53(s,3H),2.40(m,1H),2.34-2.22(m,2H),2.19(s,3H),2.15(s,7H),2.13(s,3H). 13C NMR(151MHz,DMSO-d6)δ166.50,165.44,164.00,160.63,160.16,143.99,141.79,14 0.50,137.10,135.45,132.41,130.97,130.35,130.04,129.82,128.63,128.59,126 .80,126.64,126.44,126.29,126.08,125.00,124.08,123.54,123.19,122.82,118.09,118.05,107.87,90.92,89.69,60.18,54.62,47.07,46.04,45.59,20.86,18.85.

[0125] Example 21: Preparation of 3-((2-((2-acrylamido-6-chlorophenyl)amino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0126]

[0127] The same operation as in Example 1 was performed and 75 mg of white powder was obtained by column chromatography. 1 H NMR(600MHz,DMSO-d6)δ10.48(s,1H),9.59(s,1H),9.03(s,1H),8.59(s,2H),8 .19(d,J=2.3Hz,1H),8.12(d,J=2.0Hz,1H),8.05(m,1H),7.96(m,1H),7.90(m,1 H),7.70(d,J=8.5Hz,1H),7.50(d,J=8.1Hz,1H),7.35-7.28(m,2H),6.59(m,1H) ,6.25(m,1H),5.74(m,1H),3.57(s,2H),2.53(s,3H),2.37(m,8H),2.17(s,3H). 13C NMR(151MHz,DMSO-d6)δ165.16,164.13,160.54,160.23,143.91,138.67,137. 68,133.53,132.67,132.55,132.14,131.71,130.81,130.36,128.51,128.41, 128.01,127.99,127.82,127.77,125.75,125.73,123.97,123.92,122.71,122.32,117.81,117.76,108.56,91.10,89.46,57.94,55.18,53.12,46.11,20.85.

[0128] Example 22: Preparation of (E)-3-((6-((2-(4-(dimethylamino)but-2-enamido)-6-methylphenyl)amino)pyridin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

[0129]

[0130] The same operation as in Example 1 was performed and 78 mg of white powder was obtained by column chromatography. 1 H NMR (600MHz, DMSO-d6) δ10.53(s,1H),9.46(s,1H),8.35(s,1H),8.24(d,J=2.4Hz,1H),8.23(s,1H), 8.11(d,J=2.0Hz,1H),8.07(m,1H),7.88(m,1H),7.75(d,J=8.0Hz,1H),7.70(d,J=8.6Hz,1H),7.65(m ,1H),7.48(d,J=8.1Hz,1H),7.18(t,J=7.8Hz,1H),7.12-7.07(m,1H),6.69(m,1H),6.43(s,1H),6.3 5(m,1H),3.57(s,2H),3.04(m,2H),2.51(s,3H),2.41(s,8H),2.21(s,3H),2.16(s,6H),2.14(s,3H). 13C NMR(151MHz,DMSO-d6)δ165.24,163.91,157.30,151.37,143.68,141.41,140.12,138 .69,136.92,135.70,132.56,132.41,131.69,130.59,130.44,130.30,128.11,127.97 ,127.78,126.95,126.66,126.50,125.71,123.96,123.90,123.20,121.59,117.77,117.72,108.27,92.96,88.24,60.02,57.85,55.01,52.87,49.06,45.43,20.85,18.83.

[0131] Experimental Example 1 FGFR4 kinase inhibitory activity test

[0132] In a 384-well reaction plate, positive control wells and negative control wells were set up, and different concentrations of compounds and FGFR4 kinase were added to the remaining wells. After centrifugation, the wells were incubated at room temperature for 15 minutes, and fluorescent substrates and ATP were added. After the reaction was completed, the stop solution was added to stop the reaction, and the conversion rate was read using the Caliper EZ reader. The percentage inhibition rate was then calculated using the following formula: Enzyme inhibition rate = Mean (maximum) - sample signal / Mean (maximum) - blank multiplied by 100%. The experimental results are shown in Table 1

[0133] Table 1. Inhibition rate of compounds on FGFR4 and FGFR1 at 100 and 10 nM concentrations a

[0134]

[0135]

[0136] The results showed that the inhibitory activity of compounds I-5 and I-7 on FGFR4 kinase reached more than 90% at a concentration of 100 nM, indicating that the compounds had strong inhibitory activity on FGFR4.

[0137] Experimental Example 2 Cell proliferation inhibition activity test

[0138] The experiment set up solvent control group and drug experimental group. Each drug experimental group set up 8 concentrations, and each concentration set up 3 parallel wells. Each experiment was repeated three times. In a 96-well plate, the cell concentration added to each well was 1×10 5 100 μL of cell suspension containing 3×10 cells / mL, i.e., each well contains 3×10 3When inoculating, pay attention to make the cells evenly distributed in each well. To prevent liquid evaporation, cells are not inoculated in a circle of wells around the 96-well plate, and PBS is added to keep it moist. After the cells adhere, 100 μL of the target compound of different concentrations is added to each well in the drug experimental group. The 96-well plate was placed in an incubator at 37°C and 5% CO2 for continued culture, and the culture was terminated after 72 hours. After the cells were treated with drugs for 72 hours, the 96-well plate was taken out, and the MTT solution was added to each well. After continuing to incubate in the cell culture incubator for 4 hours, the absorbance value (A) of each well was measured at 570nm on an automatic microplate reader. The inhibition rate was calculated by the formula. A linear regression analysis was performed on the inhibition rate against the drug concentration, and the IC was calculated using the linear equation. 50 The test results were expressed as mean ± standard deviation, and the experimental results were statistically analyzed using SPSS15.0 software. P < 0.05 indicated a significant difference. The results are shown in Table 2, indicating that the IC values ​​of compounds I-7 and I-21 on Huh-7 cells and Hep3B cells 50 Comparable to Ponatinib (purchased from McLean).

[0139] Table 2. Proliferation inhibition activity of compounds on different tumor cell lines a

[0140]

[0141] a The data reported are the mean values ​​from three independent experiments.

Claims

1. A selective FGFR4 inhibitor selected from the following compounds:

2. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

3. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 2 in the preparation of drugs for treating and / or preventing tumors.